TRY: Sterilisation and what else? – Commerzbank

Source Fxstreet

The Turkish lira (TRY) was hardly changed yesterday despite headlines that the central bank (CBT) had added to its liquidity management toolset by buying up liras at one of the locally operated money markets. This was CBT’s first purchase at this specific money market. The effort to sterilise excess liquidity is consistent with MPC guidance that CBT would seek additional liquidity sterilisation steps when appropriate, with the presumed aim of supporting the currency and ensuring pass-through of monetary tightening to bank lending rates, Commerzbank’s FX strategist Tatha Ghose notes.

Policymakers may be forced into harder measures

“The non-response of the lira exchange rate to liquidity tightening measures in recent months must mean that: either such factors are secondary and ineffective because the exchange rate is currently stronger than its fundamental fair-value, and is gradually finding its way to such value; or that other currency-negative factors are popping up around the same time, which is neutralising the liquidity tightening.”

“If we exclude the abrupt weakening following last year’s election, and calculate only over the subsequent, relatively-stable period, the pace of depreciation still works out to an annualised 26%. If this pace were to continue, then in a year’s time, USD/TRY could trade at 45.30. We assume that policymakers would, by then, be forced into harder measures, paradigm shifts, reforms, or more monetary tightening.”

“The latest SONAR survey reportedly shows that an increasing fraction of the electorate wants early elections. And they want this because of dissatisfaction with the economy. While respondents cite a weak economy and high inflation as urgent problems, the reality is that the economy would have to get a lot worse if inflation were to be truly controlled. There has been some base-effect driven superficial disinflation so far, but not much more.”

 

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Anthropic files for a $2 trillion IPO — the $80.7 billion loss is the decoy, the $450 billion compute bill is the riskAnthropic publicly filed its S-1 on October 26, revealing $16.29 billion of first-half revenue (+1,304% year over year) and a $80.7 billion net loss — of which $72.4 billion is a non-cash convertible-note charge. The real number is the $450 billion of signed, mostly non-cancelable compute commitments. Here is what the filing says, why NVDA, ARM and MU are the tradeable read-through, and the conditions that decide whether the AI trade passes its first public valuation test.
Author  Irene Q.
Oct 27, Tue
Anthropic publicly filed its S-1 on October 26, revealing $16.29 billion of first-half revenue (+1,304% year over year) and a $80.7 billion net loss — of which $72.4 billion is a non-cash convertible-note charge. The real number is the $450 billion of signed, mostly non-cancelable compute commitments. Here is what the filing says, why NVDA, ARM and MU are the tradeable read-through, and the conditions that decide whether the AI trade passes its first public valuation test.
placeholder
Brent's $115 front month sits $4.6 above January — the $14 spread to WTI is the supply-risk premiumDecember Brent trades at $115.29 while January is $110.71, a $4.58 backwardation. The December Brent-WTI spread is $14.2, versus a $3-5 normal. That gap, not the headline, is where the Middle East supply risk is priced. Here is what the curve says, why the December contract's expiry on October 30 will mechanically cut the headline by $4.6, and the 108.81 neckline that decides the next move.
Author  Irene Q.
Oct 28, Wed
December Brent trades at $115.29 while January is $110.71, a $4.58 backwardation. The December Brent-WTI spread is $14.2, versus a $3-5 normal. That gap, not the headline, is where the Middle East supply risk is priced. Here is what the curve says, why the December contract's expiry on October 30 will mechanically cut the headline by $4.6, and the 108.81 neckline that decides the next move.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - October 29, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 29, 2026. Read on for the details.
Author  Mitrade
Oct 29, Thu
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 29, 2026. Read on for the details.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - October 30, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 30, 2026. Read on for the details.
Author  Mitrade
Oct 30, Fri
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for October 30, 2026. Read on for the details.
placeholder
US GDP grew 3.4% and core PCE held at 3.1% — December is now a hike trade, not a cut tradeUS Q3 GDP rose 3.4%, above the 3.1% estimate, while September headline PCE hit 3.6% and core held at 3.1%. December hike odds are near 90%; inventories, AI capex and energy explain why.
Author  Irene Q.
Oct 30, Fri
US Q3 GDP rose 3.4%, above the 3.1% estimate, while September headline PCE hit 3.6% and core held at 3.1%. December hike odds are near 90%; inventories, AI capex and energy explain why.
Related Instrument
goTop
quote